RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
EyePoint Pharmaceuticals Stock

EyePoint Pharmaceuticals Net Income 2024

EyePoint Pharmaceuticals Net Income

-124.25 M USD

Ticker

EYPT

ISIN

US30233G2093

WKN

A2QJRU

In 2024, EyePoint Pharmaceuticals's profit amounted to -124.25 M USD, a 75.5% increase from the -70.8 M USD profit recorded in the previous year.

The EyePoint Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2029e193.89
2028e31.08
2027e-131.53
2026e-193.06
2025e-171.76
2024e-124.25
2023-70.8
2022-102.25
2021-58.42
2020-45.39
2019-56.79
2018-53.17
2017-18.49
2016-21.55
20156.35
2014-13.36
2013-11.9
2012-24.84
2011-8.63
20108.75
2009-2.51
2008-75.67
2007-77.69
2006-47.43
2005-12.45
2004-3.57

EyePoint Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into EyePoint Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by EyePoint Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects EyePoint Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of EyePoint Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into EyePoint Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing EyePoint Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on EyePoint Pharmaceuticals’s growth potential.

EyePoint Pharmaceuticals Revenue, EBIT and net profit per share

DateEyePoint Pharmaceuticals RevenueEyePoint Pharmaceuticals EBITEyePoint Pharmaceuticals Net Income
2029e623.4 M undefined0 undefined193.89 M undefined
2028e319.16 M undefined32.65 M undefined31.08 M undefined
2027e70.78 M undefined-160.96 M undefined-131.53 M undefined
2026e3.8 M undefined-204.59 M undefined-193.06 M undefined
2025e13.84 M undefined-188.71 M undefined-171.76 M undefined
2024e41.83 M undefined-137.77 M undefined-124.25 M undefined
202346.02 M undefined-75.07 M undefined-70.8 M undefined
202241.4 M undefined-78.94 M undefined-102.25 M undefined
202136.94 M undefined-55.28 M undefined-58.42 M undefined
202034.44 M undefined-36.7 M undefined-45.39 M undefined
201920.37 M undefined-47.86 M undefined-56.79 M undefined
20182.96 M undefined-26.27 M undefined-53.17 M undefined
20177.54 M undefined-18.11 M undefined-18.49 M undefined
20161.62 M undefined-21.77 M undefined-21.55 M undefined
201526.57 M undefined6.42 M undefined6.35 M undefined
20143.47 M undefined-13.57 M undefined-13.36 M undefined
20132.14 M undefined-12.03 M undefined-11.9 M undefined
20123.53 M undefined-10.38 M undefined-24.84 M undefined
20114.97 M undefined-10 M undefined-8.63 M undefined
201023.05 M undefined9.09 M undefined8.75 M undefined
200912.16 M undefined-4.64 M undefined-2.51 M undefined
20083.48 M undefined-24.9 M undefined-75.67 M undefined
20072.07 M undefined-102.61 M undefined-77.69 M undefined
20061.47 M undefined-27.85 M undefined-47.43 M undefined
2005620,000 undefined-14.41 M undefined-12.45 M undefined
2004270,000 undefined-6.38 M undefined-3.57 M undefined

EyePoint Pharmaceuticals stock margins

The EyePoint Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of EyePoint Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for EyePoint Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the EyePoint Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the EyePoint Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the EyePoint Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the EyePoint Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the EyePoint Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the EyePoint Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the EyePoint Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

EyePoint Pharmaceuticals Margin History

EyePoint Pharmaceuticals Gross marginEyePoint Pharmaceuticals Profit marginEyePoint Pharmaceuticals EBIT marginEyePoint Pharmaceuticals Profit margin
2029e89.93 %0 %31.1 %
2028e89.93 %10.23 %9.74 %
2027e89.93 %-227.42 %-185.84 %
2026e89.93 %-5,383.89 %-5,080.51 %
2025e89.93 %-1,363.52 %-1,241.04 %
2024e89.93 %-329.34 %-297 %
202389.93 %-163.13 %-153.84 %
202279.9 %-190.68 %-246.98 %
202177.86 %-149.65 %-158.15 %
202083.07 %-106.56 %-131.79 %
201986.79 %-234.95 %-278.79 %
201889.93 %-887.5 %-1,796.28 %
201789.93 %-240.19 %-245.23 %
201689.93 %-1,343.83 %-1,330.25 %
201589.93 %24.16 %23.9 %
201489.93 %-391.07 %-385.01 %
201389.93 %-562.15 %-556.07 %
201289.93 %-294.05 %-703.68 %
201189.93 %-201.21 %-173.64 %
201089.93 %39.44 %37.96 %
200989.93 %-38.16 %-20.64 %
200889.93 %-715.52 %-2,174.43 %
200789.93 %-4,957.01 %-3,753.14 %
200689.93 %-1,894.56 %-3,226.53 %
200589.93 %-2,324.19 %-2,008.06 %
200489.93 %-2,362.96 %-1,322.22 %

EyePoint Pharmaceuticals Aktienanalyse

What does EyePoint Pharmaceuticals do?

EyePoint Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and marketing of innovative products targeting medical and eye-related conditions. The company was founded in 1987 and is headquartered in Watertown, Massachusetts. EyePoint Pharmaceuticals has a diverse portfolio of products focused on the treatment of eye diseases. This includes products for the treatment of retinal diseases such as diabetic retinopathy, macular degeneration, and retinal vein occlusions, as well as products for preventing postoperative infections and relieving pain after eye surgeries. The business model of EyePoint Pharmaceuticals is based on the development and marketing of drugs and technologies tailored to the needs of patients and physicians in the field of ophthalmology. The company aims to improve patients' quality of life by offering innovative, safe, and effective products of the highest quality. One of EyePoint Pharmaceuticals' key technologies is the Durasert technology, which allows for controlled release of drugs over an extended period of time. This technology is utilized in many of the company's products, such as the Iluvien implant for treating diabetic retinopathy and macular degeneration. The company operates in various sectors, including ophthalmology, pain management, and ophthalmology. Each of these sectors has its own products and technologies tailored specifically to the needs of patients and physicians in those areas. A significant factor in EyePoint Pharmaceuticals' business model is partnerships with other companies and organizations that support collaboration in the development and marketing of new products. One such partnership is the joint venture with Ocumension Therapeutics, which aims to market EyePoint Pharmaceuticals' products in the Asian market. Overall, the company has introduced a variety of innovative products to the market that have had a significant impact on ophthalmology. These include products such as the Ozurdex implant for treating macular degeneration and uveitis, as well as the Dexycu injection for preventing postoperative inflammation and pain. In recent years, the company has made progress in the development of drugs for retinal diseases such as diabetic retinopathy and retinal vein occlusions. One such development is the Yutiq implant, specifically designed to slow the progression of diabetic retinopathy. Overall, EyePoint Pharmaceuticals has a significant influence on ophthalmology and plays a crucial role in the development of innovative products and technologies to improve patients' quality of life. The company will continue to play an important role in the medical industry by focusing on the development and marketing of products targeting specific needs of patients and physicians in the field of ophthalmology. EyePoint Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding EyePoint Pharmaceuticals's Profit Margins

The profit margins of EyePoint Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of EyePoint Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating EyePoint Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

EyePoint Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When EyePoint Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about EyePoint Pharmaceuticals stock

How much profit has EyePoint Pharmaceuticals made this year?

EyePoint Pharmaceuticals has made -124.25 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 75.5% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does EyePoint Pharmaceuticals publish its earnings?

EyePoint Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of EyePoint Pharmaceuticals?

The profits of EyePoint Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of EyePoint Pharmaceuticals?

You can learn more about the earnings of EyePoint Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does EyePoint Pharmaceuticals pay?

Over the past 12 months, EyePoint Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EyePoint Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of EyePoint Pharmaceuticals?

The current dividend yield of EyePoint Pharmaceuticals is .

When does EyePoint Pharmaceuticals pay dividends?

EyePoint Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of EyePoint Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is EyePoint Pharmaceuticals located?

EyePoint Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von EyePoint Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of EyePoint Pharmaceuticals from 8/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.

When did EyePoint Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/26/2024.

What was the dividend of EyePoint Pharmaceuticals in the year 2023?

In the year 2023, EyePoint Pharmaceuticals distributed 0 USD as dividends.

In which currency does EyePoint Pharmaceuticals pay out the dividend?

The dividends of EyePoint Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von EyePoint Pharmaceuticals

Our stock analysis for EyePoint Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyePoint Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.